Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

34results about How to "Achieve knockout" patented technology

Conditional gene knockout method based on CRISPR/Cas9 technology

The invention discloses a primer used for gene knockout, which comprises five groups of primer, and can be respectively shown in a SEQ NO:1, a SEQ NO:2, a SEQ NO:3, a SEQ NO:4, a SEQ NO:5, a SEQ NO:6, a SEQ NO:7, a SEQ NO:8, SEQ NO:9 and a SEQ NO:10. The invention also discloses an application of the primer in gene knockout aspect. The invention also discloses a conditional gene knockout method based on a CRISPR / Cas9 technology. The method can performing condition specificity, space-time specificity, and medicine-induced type gene modification; harm due to other cells can be reduced, function of constitutive expression gene in a specific tissue can be researched; tissue and space specificity gene knockout or induction type gene knockout can be realized by only using Cas9 tool mice; test period is short, and time and cost are saved.
Owner:CYAGEN BIOSCI INC

PCr-NHEJ (non-homologous end joining) carrier as well as construction method of pCr-NHEJ carrier and application of pCr-NHEJ carrier in site-specific knockout of bacterial genes

InactiveCN104673816AHigh gene knockout efficiencyEasy to operateBacteriaVector-based foreign material introductionCRISPR-Associated ProteinsUnclassified Bacteria
The invention belongs to the technical field of gene engineering, in particular to a pCr-NHEJ (non-homologous end joining) carrier as well as a construction method of the pCr-NHEJ carrier and an application of the pCr-NHEJ carrier in site-specific knockout of bacterial genes. The sequence of the pCr-NHEJ carrier is shown as the SEQ ID NO.1. The application of the pCr-NHEJ carrier in site-specific knockout of the bacterial genes is provided. The technical principle is as follows: NHEJ and CRISPR (clustered regularly interspaced short palindromic repeat)-Cas9 (CRISPR associated protein 9) are jointly applied, so that after DNA (deoxyribonucleic acid) is broken when a CRISPR-Cas9 system cuts bacterial genomic DNA, the NHEJ system can be connected with a broken DNA end automatically, bacteria are survived, double-strand DNA having homology with a target sequence is not required to be introduced artificially to repair the broken DNA end, and the operation steps of the CRISPR-Cas9 technique are simplified.
Owner:GUANGDONG MEDICAL UNIV

SgRNA targeting sequence of specific target pig MC4R gene and applications of sgRNA targeting sequence

The invention relates to a sgRNA targeting sequence of specific target pig MC4R gene and applications of the sgRNA targeting sequence, relating to a gRNA targeting sequence and applications. The sgRNA targeting sequence is CGTCTCGCGCTTGGACTCAG. The sgRNA targeting sequence can knock out or edit MC4R gene through a CRISPR / Cas9 system, and further eliminate the expression of MC4R, thus providing basis for preparing MC4R transgenic pigs. The sgRNA targeting sequence is applied to the field of genetic engineering.
Owner:NORTHEAST AGRICULTURAL UNIVERSITY

Construction of RIPLET knockout cell line and application of RIPLET knockout cell line as picornaviridae virus vaccine production cell line

The invention belongs to the field of gene engineering, and particularly relates to construction of an RIPLET knockout cell line and application of the RIPLET knockout cell line as a picornaviridae virus vaccine production cell line. Firstly, it is found that inhibition of RIPLET gene expression in host cells can promote replication of picornaviridae viruses, especially foot and mouth disease viruses and Seneca viruses. Secondly, the invention provides sgRNA specifically targeting RIPLET. The sgRNA can specifically target the RIPLET gene, the knockout of the RIPLET gene is realized by combining a CRISPR-Cas9 technology, and an obtained monoclonal cell line can significantly promote the replication of picornaviridae viruses, especially foot-and-mouth disease viruses and Seneca viruses. The production quantity and the antigen expression quantity of picornaviridae virus vaccines are improved, and the cell line can be used as a picornaviridae virus vaccine production cell line and has a wide application prospect.
Owner:LANZHOU INST OF VETERINARY SCI CHINESE ACAD OF AGRI SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products